Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBIO BridgeBio Pharma	$47.69 +2.6%	$38.88	$21.72 ▼ $48.68	$9.06B	1.15	2.54 million shs	3.86 million shs
JAZZ Jazz Pharmaceuticals	$111.44 +1.1%	$108.32	$95.49 ▼ $148.06	$6.74B	0.32	830,135 shs	492,176 shs
MRTX Mirati Therapeutics	$58.70	$58.82	$27.30 ▼ $64.41	$4.12B	0.77	2.76 million shs	N/A
MRVI Maravai LifeSciences	$2.67 -2.2%	$2.29	$1.67 ▼ $10.03	$679.94M	0.28	2.28 million shs	912,371 shs
UTHR United Therapeutics	$297.68 +0.7%	$301.04	$266.98 ▼ $417.82	$13.43B	0.53	444,180 shs	313,920 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBIO BridgeBio Pharma	+2.63%	+9.63%	+19.88%	+39.28%	+75.85%
JAZZ Jazz Pharmaceuticals	+1.06%	+3.57%	+2.71%	+8.29%	+5.54%
MRTX Mirati Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
MRVI Maravai LifeSciences	-2.20%	+2.69%	+25.35%	+54.34%	-70.13%
UTHR United Therapeutics	+0.73%	+2.51%	+5.06%	+4.52%	-7.37%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BBIO BridgeBio Pharma	4.6678 of 5 stars	4.5	1.0	3.9	3.3	3.3	0.6
JAZZ Jazz Pharmaceuticals	4.8255 of 5 stars	4.5	1.0	4.0	1.4	3.3	2.5
MRTX Mirati Therapeutics	0.4396 of 5 stars	0.0	0.0	4.7	0.6	0.0	0.6
MRVI Maravai LifeSciences	3.6239 of 5 stars	3.1	1.0	4.4	2.6	0.8	0.6
UTHR United Therapeutics	4.9887 of 5 stars	4.3	5.0	4.6	3.4	3.3	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBIO BridgeBio Pharma	3.00	Buy	$61.20	28.33% Upside
JAZZ Jazz Pharmaceuticals	2.92	Moderate Buy	$184.00	65.11% Upside
MRTX Mirati Therapeutics	0.00	N/A	N/A	N/A
MRVI Maravai LifeSciences	2.25	Hold	$6.64	148.65% Upside
UTHR United Therapeutics	2.69	Moderate Buy	$383.08	28.69% Upside

Current Analyst Ratings Breakdown

Latest UTHR, MRVI, JAZZ, BBIO, and MRTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/14/2025	BBIO BridgeBio Pharma	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$63.00 ➝ $68.00
7/14/2025	BBIO BridgeBio Pharma	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$70.00
7/11/2025	BBIO BridgeBio Pharma	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$58.00 ➝ $67.00
7/10/2025	UTHR United Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$348.00 ➝ $328.00
7/9/2025	BBIO BridgeBio Pharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$60.00
7/8/2025	UTHR United Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$350.00 ➝ $330.00
6/30/2025	BBIO BridgeBio Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$67.00 ➝ $76.00
6/30/2025	UTHR United Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$410.00 ➝ $385.00
6/25/2025	BBIO BridgeBio Pharma	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$50.00 ➝ $54.00
6/17/2025	BBIO BridgeBio Pharma	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$49.00
6/11/2025	JAZZ Jazz Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$202.00

(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBIO BridgeBio Pharma	$221.90M	40.81	N/A	N/A	($7.71) per share	-6.19
JAZZ Jazz Pharmaceuticals	$4.06B	1.66	$30.70 per share	3.63	$67.72 per share	1.65
MRTX Mirati Therapeutics	$12.44M	331.01	N/A	N/A	$17.31 per share	3.39
MRVI Maravai LifeSciences	$259.18M	2.62	$0.60 per share	4.42	$2.28 per share	1.17
UTHR United Therapeutics	$2.88B	4.67	$28.60 per share	10.41	$144.34 per share	2.06

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBIO BridgeBio Pharma	-$535.76M	-$3.53	N/A	N/A	N/A	-524.25%	N/A	-94.43%	7/30/2025 (Estimated)
JAZZ Jazz Pharmaceuticals	$560.12M	$7.50	14.86	5.96	4.76	11.86%	26.62%	9.14%	7/30/2025 (Estimated)
MRTX Mirati Therapeutics	-$740.87M	-$12.22	N/A	N/A	N/A	-1,900.65%	-82.15%	-67.82%	N/A
MRVI Maravai LifeSciences	-$144.85M	-$1.14	N/A	N/A	N/A	-67.14%	-12.91%	-6.87%	8/6/2025 (Estimated)
UTHR United Therapeutics	$1.20B	$25.06	11.88	10.83	6.46	40.44%	19.33%	16.73%	7/30/2025 (Estimated)

Latest UTHR, MRVI, JAZZ, BBIO, and MRTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	BBIO BridgeBio Pharma	-$0.50	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	MRVI Maravai LifeSciences	-$0.06	N/A	N/A	N/A	$47.46 million	N/A
7/30/2025	Q2 2025	JAZZ Jazz Pharmaceuticals	-$5.61	N/A	N/A	N/A	$1.05 billion	N/A
7/30/2025	Q2 2025	UTHR United Therapeutics	$6.89	N/A	N/A	N/A	$802.13 million	N/A
5/12/2025	Q1 2025	MRVI Maravai LifeSciences	-$0.07	-$0.08	-$0.01	-$0.21	$44.01 million	$46.85 million
5/6/2025	Q1 2025	JAZZ Jazz Pharmaceuticals	$4.65	$1.68	-$2.97	-$1.52	$984.16 million	$897.84 million
4/30/2025	Q1 2025	UTHR United Therapeutics	$6.29	$6.63	+$0.34	$6.63	$726.82 million	$794.40 million
4/29/2025	Q1 2025	BBIO BridgeBio Pharma	-$1.00	-$0.88	+$0.12	-$0.88	$57.14 million	$36.74 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
JAZZ Jazz Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MRTX Mirati Therapeutics	N/A	N/A	N/A	N/A	N/A
MRVI Maravai LifeSciences	N/A	N/A	N/A	N/A	N/A
UTHR United Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBIO BridgeBio Pharma	N/A	4.57	4.54
JAZZ Jazz Pharmaceuticals	1.28	3.38	2.97
MRTX Mirati Therapeutics	N/A	7.54	7.40
MRVI Maravai LifeSciences	0.60	5.96	5.17
UTHR United Therapeutics	N/A	5.46	5.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBIO BridgeBio Pharma	99.85%
JAZZ Jazz Pharmaceuticals	89.14%
MRTX Mirati Therapeutics	N/A
MRVI Maravai LifeSciences	50.25%
UTHR United Therapeutics	94.08%

Insider Ownership

Company	Insider Ownership
BBIO BridgeBio Pharma	18.20%
JAZZ Jazz Pharmaceuticals	4.30%
MRTX Mirati Therapeutics	3.26%
MRVI Maravai LifeSciences	2.11%
UTHR United Therapeutics	10.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBIO BridgeBio Pharma	400	189.88 million	155.32 million	Optionable
JAZZ Jazz Pharmaceuticals	2,800	60.51 million	57.91 million	Optionable
MRTX Mirati Therapeutics	587	70.15 million	67.86 million	Optionable
MRVI Maravai LifeSciences	610	254.66 million	249.29 million	Optionable
UTHR United Therapeutics	1,305	45.11 million	40.46 million	Optionable

UTHR, MRVI, JAZZ, BBIO, and MRTX Headlines

Recent News About These Companies

Paul A. Mahon Sells 11,000 Shares of United Therapeutics Corporation (NASDAQ:UTHR) Stock

July 14 at 7:16 PM | marketbeat.com

6,585 Shares in United Therapeutics Corporation (NASDAQ:UTHR) Bought by Aurora Investment Counsel

July 14 at 6:41 AM | marketbeat.com

Emerald Advisers LLC Sells 1,061 Shares of United Therapeutics Corporation (NASDAQ:UTHR)

July 14 at 5:41 AM | marketbeat.com

Morgan Stanley Cuts United Therapeutics (NASDAQ:UTHR) Price Target to $328.00

July 13 at 2:03 AM | americanbankingnews.com

Nisa Investment Advisors LLC Sells 4,544 Shares of United Therapeutics Corporation (NASDAQ:UTHR)

July 12 at 5:08 AM | marketbeat.com

United Therapeutics’ DeciPHer-ILD Study: A New Frontier in Pulmonary Hypertension Research

July 11, 2025 | tipranks.com

Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term

July 11, 2025 | zacks.com

Weil Company Inc. Buys 3,298 Shares of United Therapeutics Corporation (NASDAQ:UTHR)

July 11, 2025 | marketbeat.com

1,822 Shares in United Therapeutics Corporation (NASDAQ:UTHR) Acquired by Rehmann Capital Advisory Group

July 11, 2025 | marketbeat.com

UBS Trims Price Target but Stays Bullish on United Therapeutics (UTHR)

July 10, 2025 | insidermonkey.com

J.P. Morgan Sticks to Their Buy Rating for United Therapeutics (UTHR)

July 10, 2025 | theglobeandmail.com

Morgan Stanley Has Lowered Expectations for United Therapeutics (NASDAQ:UTHR) Stock Price

July 10, 2025 | marketbeat.com

United Therapeutics’ Phase 3 Study on Inhaled Treprostinil for Pulmonary Fibrosis: Key Insights for Investors

July 9, 2025 | tipranks.com

United Therapeutics Corporation (NASDAQ:UTHR) Shares Bought by TD Private Client Wealth LLC

July 9, 2025 | marketbeat.com

World Investment Advisors Has $718,000 Stake in United Therapeutics Corporation (NASDAQ:UTHR)

July 9, 2025 | marketbeat.com

Teacher Retirement System of Texas Sells 1,343 Shares of United Therapeutics Corporation (NASDAQ:UTHR)

July 9, 2025 | marketbeat.com

United Therapeutics (NASDAQ:UTHR) Price Target Cut to $330.00 by Analysts at JPMorgan Chase & Co.

July 8, 2025 | marketbeat.com

Brookstone Capital Management Makes New $1.48 Million Investment in United Therapeutics Corporation (NASDAQ:UTHR)

July 7, 2025 | marketbeat.com

Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?

July 4, 2025 | zacks.com

New York State Teachers Retirement System Lowers Holdings in United Therapeutics Corporation (NASDAQ:UTHR)

July 3, 2025 | marketbeat.com

United Therapeutics Corporation (NASDAQ:UTHR) Holdings Raised by Sumitomo Mitsui Trust Group Inc.

July 3, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

UTHR, MRVI, JAZZ, BBIO, and MRTX Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

$47.69 +1.22 (+2.63%)

Closing price 07/14/2025 04:00 PM Eastern

Extended Trading

$48.36 +0.66 (+1.39%)

As of 07/14/2025 07:50 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Jazz Pharmaceuticals NASDAQ:JAZZ

$111.44 +1.17 (+1.06%)

Closing price 07/14/2025 04:00 PM Eastern

Extended Trading

$111.45 +0.01 (+0.01%)

As of 07/14/2025 04:27 PM Eastern

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Mirati Therapeutics NASDAQ:MRTX

Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

Maravai LifeSciences NASDAQ:MRVI

$2.67 -0.06 (-2.20%)

Closing price 07/14/2025 04:00 PM Eastern

Extended Trading

$2.64 -0.03 (-1.16%)

As of 07/14/2025 07:56 PM Eastern

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

United Therapeutics NASDAQ:UTHR

$297.68 +2.16 (+0.73%)

Closing price 07/14/2025 04:00 PM Eastern

Extended Trading

$297.38 -0.30 (-0.10%)

As of 07/14/2025 07:50 PM Eastern

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time